Company research
Virax Biolabs Group Ltd
CIK 1885827Updated Oct 30, 2026
SecurityVRAX · NASDAQ · equity
Name history
Virax Biolabs (Cayman) Ltd · through Dec 27, 2021
VRAX price & chart
Loading TradingView…
NASDAQ:VRAX on TradingView ↗About the company
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune™, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.
In the news
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -6,067,232Source | -6,739,120Source | -5,457,763Source | -1,749,870Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 337,576Source | — | — | 928Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 129,276Source | -572,246Source | — | 641,156Source |
| AdjustmentsForSharebasedPaymentsUSD | 365,309Source | 1,011,973Source | 1,734,601Source | 290,364Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | 123,743Source | 3,668Source | 111Source | 5,657Source |
| GeneralAndAdministrativeExpenseUSD | 4,330,028Source | 4,594,743Source | 5,307,671Source | 1,286,118Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | -78,953Source | 6,104Source | 15,468Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 107,756Source | 56,366Source | — | — |
| ProceedsFromIssuingSharesUSD | 5,128,186Source | 234Source | 13,654,347Source | 519,613Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 178,403Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | — |
| Total Revenue | — | — | — | — |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareUSD per share | -1.62Source | -3.36Source | -0.51Source | — |
| DepreciationAndAmortisationExpenseUSD | 266,601Source | 54,870Source | — | — |
| DilutedEarningsLossPerShareUSD per share | -1.62Source | -3.36Source | -0.51Source | — |
| EmployeeBenefitsExpenseUSD | 365,309Source | 1,011,973Source | 1,734,601Source | — |
| GeneralAndAdministrativeExpenseUSD | 4,330,028Source | 4,594,743Source | 5,307,671Source | 1,286,118Source |
| GrossProfitUSD | -53,067Source | 50,590Source | -1,365Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | 390,355Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | -136,661Source | — | — | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 45,600Source | 26,347Source | — | — |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -5,985Source | -5,583Source | -269Source | -41,043Source |
| ProfitLossAttributableToOwnersOfParentUSD | -6,061,247Source | -6,733,537Source | -5,457,494Source | -1,708,827Source |
| ProfitLossBeforeTaxUSD | -6,203,893Source | -6,739,120Source | -5,457,763Source | -1,749,870Source |
| ProfitLossFromOperatingActivitiesUSD | -6,162,897Source | -6,496,473Source | -5,732,761Source | -1,733,679Source |
| ResearchAndDevelopmentExpenseUSD | 1,779,802Source | 1,561,965Source | 397,109Source | 433,743Source |
| SellingExpenseUSD | — | — | 26,616Source | 13,818Source |
Offerings
Registration 333-297684
Filing attachments
vrax-ex99_1.htm · 6-K · 2026-10-29
Exhibit 99.1 Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China Three new distributor agreements build on initial China sales and extend the Company’s distributor-led commercial strategy LONDON, 29 October, 2026 /PRNewswire/ - Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJe…
Read attachment ↗vrax-ex99_1.htm · 6-K · 2026-07-31
Exhibit 99.1 Virax Biolabs Group Limited (Incorporated under the laws of the Cayman Islands) Notice of Extraordinary General Meeting of Shareholders To Be Held on August 14, 2026, at 2:00 p.m., local time NOTICE IS HEREBY GIVEN THAT the Extraordinary General Meeting (the “Meeting”) of the holders (the "shareholders") of the ordinary shares of par value US$0.025 each (the “Ordinary Shares”) of Virax Biolabs Group Limited (the “Company”) will be held at BioCity Glasgow, Bo’Ness Road, Newhouse…
Read attachment ↗vrax-ex99_1.htm · 6-K · 2026-07-16
Exhibit 99.1 Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement - Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders’ equity attributable to ordinary shareholders of $7.3 million - Fosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian markets - Preferred …
Read attachment ↗vrax-ex4_1.htm · 6-K · 2026-07-10
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗vrax-ex4_2.htm · 6-K · 2026-07-10
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗